PH12015502508A1 - Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions - Google Patents
Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositionsInfo
- Publication number
- PH12015502508A1 PH12015502508A1 PH12015502508A PH12015502508A PH12015502508A1 PH 12015502508 A1 PH12015502508 A1 PH 12015502508A1 PH 12015502508 A PH12015502508 A PH 12015502508A PH 12015502508 A PH12015502508 A PH 12015502508A PH 12015502508 A1 PH12015502508 A1 PH 12015502508A1
- Authority
- PH
- Philippines
- Prior art keywords
- compositions
- methods
- staphylococcus aureus
- capsular polysaccharide
- aureus serotype
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 2
- 241000191967 Staphylococcus aureus Species 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 2
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 abstract 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21915109P | 2009-06-22 | 2009-06-22 | |
| US21914309P | 2009-06-22 | 2009-06-22 | |
| PCT/US2010/039473 WO2011041003A2 (en) | 2009-06-22 | 2010-06-22 | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502508A1 true PH12015502508A1 (en) | 2019-06-03 |
Family
ID=43599164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502508A PH12015502508A1 (en) | 2009-06-22 | 2015-11-02 | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| PH12021551159A PH12021551159A1 (en) | 2009-06-22 | 2021-05-20 | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021551159A PH12021551159A1 (en) | 2009-06-22 | 2021-05-20 | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9125951B2 (enExample) |
| EP (2) | EP3461496B1 (enExample) |
| JP (4) | JP2012530785A (enExample) |
| KR (2) | KR101774062B1 (enExample) |
| CN (1) | CN102625713A (enExample) |
| AR (1) | AR077190A1 (enExample) |
| AU (1) | AU2010301043B2 (enExample) |
| BR (1) | BRPI1011753B8 (enExample) |
| CA (1) | CA2766418C (enExample) |
| CO (1) | CO6480930A2 (enExample) |
| ES (2) | ES2729934T3 (enExample) |
| IL (1) | IL217085B (enExample) |
| MX (1) | MX2012000045A (enExample) |
| MY (1) | MY158231A (enExample) |
| NZ (1) | NZ597191A (enExample) |
| PE (1) | PE20110065A1 (enExample) |
| PH (2) | PH12015502508A1 (enExample) |
| RU (1) | RU2531234C2 (enExample) |
| SA (1) | SA114350400B1 (enExample) |
| SG (2) | SG177310A1 (enExample) |
| TW (2) | TWI505834B (enExample) |
| WO (1) | WO2011041003A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5395264B2 (ja) | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物 |
| BR112012009014B8 (pt) * | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
| WO2011051917A1 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| CA2881420C (en) | 2012-08-16 | 2016-11-15 | Pfizer Inc. | Glycoconjugation processes and compositions |
| MX364644B (es) | 2012-11-21 | 2019-05-03 | Serum Inst India Ltd | Produccion de altos rendimientos de polisacaridos bacteriales. |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| US20160324949A1 (en) * | 2014-01-21 | 2016-11-10 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| WO2015175565A2 (en) * | 2014-05-12 | 2015-11-19 | Purdue Research Foundation | Selectin and icam/vcam peptide ligand conjugates |
| AR104469A1 (es) | 2014-08-08 | 2017-07-26 | Glycovaxyn Ag | Células huésped modificadas para su uso en producción de bioconjugados |
| BE1023004A1 (fr) | 2014-12-10 | 2016-10-31 | Glaxosmithkline Biologicals Sa | Procede de traitement |
| KR102045663B1 (ko) * | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| TWI756893B (zh) * | 2015-07-21 | 2022-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| WO2017140683A2 (en) * | 2016-02-15 | 2017-08-24 | Hipra Scientific, S.L.U. | Streptococcus uberis extract as an immunogenic agent |
| MX2018010920A (es) * | 2016-03-15 | 2019-03-06 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos. |
| CA3050120A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
| US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| CN111065387B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| CN111093649B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| BR112020004410A8 (pt) * | 2017-09-07 | 2023-01-31 | Merck Sharp & Dohme | Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora |
| US11896656B2 (en) * | 2018-04-30 | 2024-02-13 | Merck Sharp & Dohme Llc | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| US20210252125A1 (en) | 2018-04-30 | 2021-08-19 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| WO2019212842A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| EP4107192A1 (en) | 2020-02-21 | 2022-12-28 | Pfizer Inc. | Purification of saccharides |
| CN111228478A (zh) * | 2020-02-25 | 2020-06-05 | 江南大学 | 三糖重复单元寡糖链在制备金黄色葡萄球菌疫苗中的应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| EP4346893A2 (en) * | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US150688A (en) | 1874-05-12 | Improvement in centrifugal machines | ||
| US4134214A (en) | 1977-08-05 | 1979-01-16 | Merck & Co., Inc. | Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
| IL78775A (en) | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2047031A1 (en) | 1990-07-19 | 1992-01-20 | Stephen Marburg | Peptide-polysaccharide-protein conjugate vaccines |
| NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| CA2123811C (en) | 1991-11-22 | 2005-07-05 | Ali Ibrahim Fattom | Type i and type ii surface antigens associated with staphylococcus epidermidis |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| NZ274376A (en) | 1993-09-22 | 1997-11-24 | Jackson H M Found Military Med | Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1996014873A2 (en) * | 1994-11-16 | 1996-05-23 | Sri International | COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY |
| BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| IL121585A0 (en) * | 1995-06-07 | 1998-02-08 | Alberta Res Council | Immunogenic and immunostimulatory oligosaccharide compositions and methods of preparing and using them |
| GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2293739A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| EP1000076A1 (en) | 1997-07-17 | 2000-05-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1 |
| EP2319931A1 (en) | 1997-11-26 | 2011-05-11 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US7252828B2 (en) | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| BR9913340A (pt) | 1998-08-31 | 2001-11-06 | Inhibitex Inc | Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| EP1035137A1 (en) | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| IL145043A0 (en) | 1999-03-19 | 2002-06-30 | Smithkline Beecham Biolog | Vaccine |
| US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
| US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
| EP2295407B1 (en) | 2000-03-22 | 2014-11-05 | Solulink, Inc. | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| HU228264B1 (en) | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| KR20030096292A (ko) * | 2001-03-27 | 2003-12-24 | 덴드레온 샌 디에고 엘엘씨 | 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
| CN1977971A (zh) | 2001-06-07 | 2007-06-13 | 惠氏控股有限公司 | 作为佐剂的霍乱全毒素的突变体形式 |
| BR0210216A (pt) | 2001-06-07 | 2004-06-08 | Wyeth Corp | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante |
| CA2351018A1 (en) | 2001-07-09 | 2003-01-09 | Universite De Sherbrooke | Dna vaccine against staphylococcus aureus |
| FR2828404B1 (fr) | 2001-08-10 | 2005-07-15 | Neovacs | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
| US20030113350A1 (en) | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
| US20030092062A1 (en) * | 2001-10-24 | 2003-05-15 | Reddy M. Parameswara | Immobilizing biological molecules |
| CA2480389C (en) | 2002-03-26 | 2012-10-09 | Chiron Srl | Modified saccharides having improved stability in water |
| TW200306314A (en) | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| GB0220198D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
| CN100351260C (zh) | 2002-11-12 | 2007-11-28 | 布赖汉姆妇女医院 | 葡萄球菌感染的多糖疫苗 |
| JP4078417B2 (ja) | 2003-03-04 | 2008-04-23 | 独立行政法人産業技術総合研究所 | 好熱菌由来オリゴペプチダーゼ |
| NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| CN1747748B (zh) * | 2003-05-23 | 2011-01-19 | 尼克塔治疗公司 | 具有特定原子排列的聚合物衍生物 |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| AR046960A1 (es) | 2003-12-17 | 2006-01-04 | Wyeth Corp | Metodos para producir los conjugados portadores de peptidos inmunogenicos |
| US7537766B2 (en) | 2004-08-30 | 2009-05-26 | Wyeth | Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof |
| JP2008513406A (ja) * | 2004-09-22 | 2008-05-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
| KR20130122810A (ko) * | 2005-06-27 | 2013-11-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
| AR060187A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| MY148405A (en) * | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0606416D0 (en) * | 2006-03-30 | 2006-05-10 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| FR2899110A1 (fr) * | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
| WO2007127668A2 (en) | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| SI2436700T1 (sl) | 2007-03-23 | 2018-09-28 | Wyeth Llc | Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae |
| ES2615390T3 (es) | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| JP5395264B2 (ja) * | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物 |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| WO2011051917A1 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
| CN103826656B (zh) | 2010-12-22 | 2015-08-26 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的稳定的免疫原性组合物 |
-
2010
- 2010-06-22 EP EP18200872.2A patent/EP3461496B1/en active Active
- 2010-06-22 ES ES10803414T patent/ES2729934T3/es active Active
- 2010-06-22 TW TW099120434A patent/TWI505834B/zh not_active IP Right Cessation
- 2010-06-22 CN CN2010800372767A patent/CN102625713A/zh active Pending
- 2010-06-22 CA CA2766418A patent/CA2766418C/en active Active
- 2010-06-22 NZ NZ59719110A patent/NZ597191A/xx not_active IP Right Cessation
- 2010-06-22 EP EP10803414.1A patent/EP2445523B1/en not_active Not-in-force
- 2010-06-22 BR BRPI1011753A patent/BRPI1011753B8/pt not_active IP Right Cessation
- 2010-06-22 TW TW104127997A patent/TW201544119A/zh unknown
- 2010-06-22 RU RU2011152045/10A patent/RU2531234C2/ru active
- 2010-06-22 AU AU2010301043A patent/AU2010301043B2/en not_active Ceased
- 2010-06-22 AR ARP100102197 patent/AR077190A1/es active IP Right Grant
- 2010-06-22 US US13/379,291 patent/US9125951B2/en active Active
- 2010-06-22 JP JP2012517649A patent/JP2012530785A/ja active Pending
- 2010-06-22 SG SG2011094968A patent/SG177310A1/en unknown
- 2010-06-22 MX MX2012000045A patent/MX2012000045A/es active IP Right Grant
- 2010-06-22 PE PE2010000421A patent/PE20110065A1/es active IP Right Grant
- 2010-06-22 SG SG10201406432RA patent/SG10201406432RA/en unknown
- 2010-06-22 KR KR1020127001730A patent/KR101774062B1/ko not_active Expired - Fee Related
- 2010-06-22 ES ES18200872T patent/ES2959890T3/es active Active
- 2010-06-22 KR KR20147024052A patent/KR20140119165A/ko not_active Ceased
- 2010-06-22 MY MYPI2011006233A patent/MY158231A/en unknown
- 2010-06-22 WO PCT/US2010/039473 patent/WO2011041003A2/en not_active Ceased
- 2010-06-22 SA SA114350400A patent/SA114350400B1/ar unknown
-
2011
- 2011-12-19 IL IL217085A patent/IL217085B/en active IP Right Grant
- 2011-12-22 CO CO11177205A patent/CO6480930A2/es not_active Application Discontinuation
-
2013
- 2013-08-02 JP JP2013161040A patent/JP2013237693A/ja active Pending
-
2015
- 2015-07-28 US US14/811,017 patent/US9623100B2/en active Active
- 2015-10-20 JP JP2015205977A patent/JP6153581B2/ja not_active Expired - Fee Related
- 2015-11-02 PH PH12015502508A patent/PH12015502508A1/en unknown
-
2017
- 2017-05-30 JP JP2017106213A patent/JP6393804B2/ja not_active Expired - Fee Related
-
2021
- 2021-05-20 PH PH12021551159A patent/PH12021551159A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551159A1 (en) | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions | |
| AR060187A1 (es) | Composicion inmunogenica | |
| MX2023001947A (es) | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. | |
| NZ588884A (en) | Cross-linkers and their uses | |
| ZA201907233B (en) | Conjugation of a cytotoxic drug with bis-linkage | |
| MY148405A (en) | Immunogenic composition | |
| MX2020002555A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
| MY169837A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
| NO20071610L (no) | Immunogen sammensetning | |
| DK2283857T3 (da) | Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider | |
| EP4286000A3 (en) | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof | |
| ZA201206504B (en) | Immunogenic composition comprising s. pneumoniae polysaccharides conjugates to carrier proteins | |
| CL2012000744A1 (es) | Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende. | |
| MX2014009250A (es) | Composicion inmunogenica. | |
| MX2009006410A (es) | Conjugados de polimero-oligonucleotido, proteina y/o peptido. | |
| IN2014DN09791A (enExample) | ||
| ZA202103560B (en) | Multivalent pneumococcal polysaccharide-protein conjugate vaccine | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| WO2006096970A8 (en) | Synthetic anti-candida albicans oligosaccharide based vaccines | |
| UA97359C2 (en) | Immunogenic composition | |
| WO2010022320A3 (en) | Polymeric benzyl carbonate-derivatives | |
| TW200806314A (en) | Immunogenic composition | |
| ZA201200451B (en) | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |